

SUB
D2

consisting of:

13. (Amended) A composition comprising:
- (a) an isolated polynucleotide comprising a sequence selected from the group
- (i) the polynucleotide recited in SEQ ID NO:198;
 - (ii) complements of the foregoing polynucleotide;
 - (iii) sequences consisting of at least 50 contiguous residues of SEQ ID NO:198; and
 - (iv) sequences having at least 90% identity to SEQ ID NO:198; and
- (b) a physiologically acceptable carrier,
- wherein said polynucleotide is useful in the detection of ovarian cancer.

B3
SUB
D3

22. (Amended) An isolated polynucleotide encoding a fusion protein wherein said polynucleotide comprises a sequence selected from the group consisting of:
- (a) the polynucleotide recited in SEQ ID NO:198;
 - (b) complements of the foregoing polynucleotide; and
 - (c) sequences having at least 90% identity to the entirety of SEQ ID NO:198,
- wherein said polynucleotide is useful in the detection of ovarian cancer.

B4
SUB
D4

65. (Amended) A diagnostic kit for the detection of ovarian cancer, comprising:
- (a) an oligonucleotide comprising 10 to 40 nucleotides that hybridize under moderately stringent conditions to a polynucleotide comprising a sequence selected from the group consisting of:
- (i) the polynucleotide recited in SEQ ID NO:198;
 - (ii) complements of the foregoing polynucleotide;
 - (iii) sequences consisting of at least 50 contiguous residues of SEQ ID NO:198; and
 - (iv) sequences having at least 90% identity to SEQ ID NO:198; and
- (b) a detection reagent for use in a polymerase chain reaction or hybridization assay,